Trandolapril 4 mg Tablet Under Non-Fasting Conditions

Summary

The objective of this study is to evaluate the comparative bioavailability between trandolapril 4 mg tablets (test) and Mavik® 4 mg Tablets (reference) after a single-dose in healthy subjects under fed conditions.

Timeline

Start

2004-10

Primary completion

2004-11

Completion

2004-11

Outcome

Met primary endpoint

registry Ratio of Geometric Means 96.00 (90% CI 85.13 to 108.27) NCT00840073 ↗

registry Ratio of Geometric Means 103.81 (90% CI 96.72 to 111.41) NCT00840073 ↗

registry Ratio of Geometric Means 102.37 (90% CI 97.34 to 107.65) NCT00840073 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	trandolapril	Small molecule	4 mg	—

Indications

No indication recorded.